Skip to main content
. 2022 Oct 27;146(2):448–454. doi: 10.1093/brain/awac386

Figure 3.

Figure 3

The MNK inhibitor, eFT508, reduces dural IL-6 -induced facial hypersensitivity and prevents priming to pH 7.0. Female and male WT mice were administered 5 µl of dural IL-6 (0.1 ng) or vehicle and tested for acute facial hypersensitivity and grimacing. Upon returning to baseline thresholds, mice were tested for priming with a 5 µl dural injection of SIF (pH = 7.0). Prior to IL-6 (A) or pH 7.0 (D), mice received 100 µl of the MNK inhibitor, eFT508 (10 mg/kg), or vehicle via oral gavage. In mice that received eFT508, dural IL-6 induced facial hypersensitivity (B) and grimace measures (C) were significantly attenuated compared to the vehicle group and these mice did not prime to dural pH 7.0. Similarly, mice that received eFT508 prior to dural pH 7.0 did not prime to pH 7.0 compared to the vehicle group (E–F), suggesting that activation of MNK is critical to transition to a primed state. No sex differences were observed. Comparisons were made via two-way ANOVA followed by Bonferroni post hoc analysis. Significance between IL-6/Vehicle and IL-6/eFT508 groups (denoted by asterisk) and SIF/eFT508 and IL-6/eFT508 groups (denoted by delta symbol) is shown. n = 7 for all groups; *,ΔP ≤ 0.05; **,ΔΔP ≤ 0.01; ***,ΔΔΔP ≤ 0.001; ****,ΔΔΔΔP ≤ 0.0001.